News
RNAZ
8.58
+0.23%
0.02
Weekly Report: what happened at RNAZ last week (0706-0710)?
Weekly Report · 1d ago
Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch
NASDAQ · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 07/06 17:05
Weekly Report: what happened at RNAZ last week (0629-0703)?
Weekly Report · 07/06 09:22
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps
TipRanks · 07/02 20:34
TransCode Therapeutics adjourns annual shareholder meeting to July 20 pending Nasdaq review
PUBT · 07/02 20:07
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch
NASDAQ · 07/02 03:16
Top Biotech Gainers: ABVX Soars On UC Trial Data, PMN Eyes Alzheimer's Catalyst, TRAX In Focus
NASDAQ · 07/01 02:40
Weekly Report: what happened at RNAZ last week (0622-0626)?
Weekly Report · 06/29 09:21
Weekly Report: what happened at RNAZ last week (0615-0619)?
Weekly Report · 06/22 09:24
TransCode Therapeutics publishes investor presentation on RNA therapeutics, cancer vaccines and oncolytic immunotherapy platforms
PUBT · 06/18 15:49
TransCode Highlights Progress of Lead RNA Cancer Therapeutic
TipRanks · 06/18 12:39
Weekly Report: what happened at RNAZ last week (0608-0612)?
Weekly Report · 06/15 09:24
Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch
NASDAQ · 06/11 03:03
Weekly Report: what happened at RNAZ last week (0601-0605)?
Weekly Report · 06/08 09:22
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Barchart · 06/08 07:04
Transcode reports results from Phase 1a dose escalation trial with TTX-MC138
TipRanks · 06/03 13:30
Pre-Market Movers: PMI, CNTB, RNAZ Chart The Course
NASDAQ · 06/03 13:10
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a
TipRanks · 06/03 12:31
More
Webull provides a variety of real-time RNAZ stock news. You can receive the latest news about Transcode Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.